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BIOCHEMICAL MAPPING OF THE MEASLES VIRUS H AND F ENVELOPE
GLYCOPROTEIN PROTEIN-PROTEIN INTERFACE.
by
NEHA ARUN PANCHBHAI.
Under the direction of Richard K. Plemper.
ABSTRACT
The Paramyxoviridae family includes several viruses that are important to human health,
including measles virus. The envelope glycoproteins are essential for attachment and entry of the
virus into the host cell [1, 2]. To develop novel therapeutics against the virus, detailed knowledge
of envelope glycoprotein protein-protein interaction is important. The goal of this study is to
characterize the MeV entry machinery on a molecular level. Interaction of haemaglutinin (H) and
fusion (F) protein in pre-fusion form can be biochemically detected with DTSSP. To map the
interaction site of H and F protein in pre-fusion form, we have mutated lysine (K) to arginine (R)
in the F protein, and examined surface expression. The mutated F was still expressed on the
surface and amount of surface expression correlated with fusion activity. The altered F proteins
produced in this study will be used to further characterize the H-F interaction.
INDEX WORDS: - Measles, Glycoproteins, haemaglutinin (H) and fusion (F) protein, DTSSP.
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1.

INTRODUCTION

The measles is one of the most contagious human disease known to man. Its R

value is

10-12. [3] After the vaccine for measles is developed (1963) the outbreaks of measles have been
reduced significantly and so as the death rate due to measles. As this I completely human disease
and the virus have no animal reservoir it is possible to irradiate the disease from the surface of
the earth. But due to good vaccination programs less frequent outbreaks of the disease are seen
recently and therefore people are forgetting about the impact of the disease on human society.
Because of this reason now a-days people are refusing to get vaccinated against the measles. As
a result of this now we can see more frequent outbreaks of measles. To avoid complications from
the measles and also to avoid big measles outbreak once again, novel therapeutics have to be
discover. To develop anti measles inhibitory drug, detailed knowledge of entry mechanism of the
measles virus is important.
1.1. Epidemiology of Measles
The disease Measles is caused by the Measles Virus. It is an acute type of highly
infectious disease found in humans but not in other animals.[2] In 10th century Persian
physician Rhazes described measles as “more dreaded than smallpox.” [2, 4] Figure 1 shows
the worldwide measles occurrence in 2013.
‘The basic reproductive number R

is the average number of individuals directly

infected by one infectious case (secondary cases) during the entire infectious period, when the
infectious agent has entered a totally susceptible population’ [5]. R
[6].

for the measles is 11-18
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Figure 1 Worldwide map showing cases of measles outbreak in 2013 [7].

1.2. Signs and symptoms of Measles
The measles infection starts at epithelial lining of nose and the lungs. [2] Within 3-4 days
it spreads in lymph nodes and rash starts to appear on 10-12th day. [2] The viremia starts to
appear on day 3 and spread the infection in retinal tissues. [2, 4] on second viremia stage (day
5-7) the infection spread across the other parts of the body.
Measles virus takes 10-12 days of incubation period from initial infection to prodrome
[4], After the 10-12 days of incubation, symptoms of measles starts to appear with high
temperature (about 104⁰C), usually coupled with runny nose, cough and conjunctivitis. [4]
Koplik spots starts to appear inside the mouth and chicks. After 1-2 days red rash starts to
appear starting from hair lining of the face towards hands and legs which lasts for 5-6 days.[2,
4] After 5-6 days rash starts to fade up starting from face towards the extremities.
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Complications from measles can occur in young children under the age of 5, in adult
over 20 years old, unborn child if the mother gets measles during pregnancy, immunity
compromised people, etc.[2, 4] Blindness encephalitis, diarrhea, pneumonia, ear infection,
miscarriage are the few examples of complications. [2, 4] According to the WHO report
measles has 1/1000 of the death rate. The risk increases in malnourished children and with
poor healthcare facilities.[2]
1.3. Treatments available for Measles
There is no specific treatment for measles.[2] To maintain the body fluid that is lost
during diarrhea or other complications from measles can be prevented by proper fluid intake.
[2] There are antibiotics to prevent from eye, ear infection or bacterial infection. Vitamin A
supplements can prevent eye damage from measles. [2] It has also shown that Vitamin A
supplements can decrease the death rate from measles by 50%. [2]
Measles can be prevented from measles’s vaccine. In 1963 first 2 types of measles
vaccines were licensed in U.S. First is inactivated vaccine and the other is live attenuated
vaccine. [4] The inactivated vaccine was not very successful in preventing measles so it was
removed from the market in 1967.[4] The live attenuated Edmonston B vaccine was also
giving complications after people getting vaccinated. So in 1968 more attenuated vaccine using
Edmonston-Enders strains of measles virus was introduced.[4] Now In the U.S. live more
attenuated measles vaccine called as “Morten” is available. It is given in combination with
mumps and rubella vaccines and together known as MMRV. This vaccine gives lifelong
immunity from measles.[4] The chick embryo’s fibroblast tissues are used to culture measles
vaccine.[4]
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1.4. Measles vaccine efficacy
Measles vaccine should be given after the first birthday. Vaccinating before the age of
12 month does not create immunity against measles.[4] Two doses of the vaccine separated by
4-6 weeks are necessary and highly recommended to create full immunity against measles. [4]
Failure of the vaccine can be seen in immunologically compromised persons or at old
age when immunity starts to decline. The vaccine given before the age of 12 months fail to
create full immunity against measles because at that age the child has passive immunity from
his mother. Only one dose of the vaccine does not create sufficient antibody tiers in the body,
second booster is necessary.
1.5. Measles Virus
Measles virus belongs to the genus Morbillivirus in the family Paramyxoviridae. It is an
enveloped virus with a helical shaped capsid. Its genome is a negative sense single-stranded
RNA. The envelope contains two glycoproteins, the attachment protein, haemaglutinin (H),
and the fusion protein (F).[1] H and F are responsible for attachment of the virus to the host
cell and membrane fusion. The matrix protein (M) either surrounds the nucleocapsid or coats
the interior membrane. Genome is encapsidated by nucleocapsid proteins (N) and associated
with the large (L) and phospho (P) protein [1]
The virus cannot survive in the air for more than 2 hr. It is highly sensitive towards
heat, acidic pH, light, ether, Trypsin etc. [2]
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Figure 2: Structure of Measles Virus showing different proteins and viral RNA [4]
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1.6 Fusion protein of Measles
MeV F has homology model based on the crystal structure of PIV5 F protein (citation).
It is a class I membrane fusion protein. It is formed from 3 monomers linked together with
hydrophobic interactions to form a homotrimer. It has 2 major domains F1 and F2 linked
together with disulfide linkage. F1 is embedded in viral membrane forming transmembrane
domain and F2 forms extracellular domain. [8-10] The homology model shows that it has a
globular head attached to membrane through helical stalk. The stalk is made from membraneproximal heptad repeat (HR)-B linker domain. [11] In its pre-fusion form it coexists and is
attached with H on the viral membrane.[8] After H binds with the cell receptor it triggers
conformational changes in F resulting F in to the post-fusion form.
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HRA
F₂
Fusion peptide

N-termini

HRB

Transmembrane domain

Figure 3 : Structure of Fusion protein MeV. A homology model of MeV F based on the crystal
structure of PIV5 F protein. Model is build using Pymol algorithm.
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1.7. Folding of F from pre- fusion to post-fusion form during the fusion event
As a classical example of class I membrane fusion protein, in pre-fusion form MeV F
exist as a homotrimer. But in the post-fusion form it forms 6 helix bundle [12]. In order to
facilitate the membrane fusion, the pre-fusion form of the F has to undergo large conformational
changes [12]. When H attaches to the receptor protein it creates conformational changes in the F.
The HRA region (different regions of the F shown in Figure 3) extends towards the cell
membrane exposing the fusion peptide which is hydrophobic in nature and tucked into the head
domain of the F in the pre-fusion form which then get inserted in the hydrophobic region of the
host cell membrane attaching the fusion protein to the host cell membrane at N-terminus domain
and to the viral cell membrane at the C-terminal domain resulting into formation of the prehairpin structure [12]. Then the HRB region folds backward towards the fusion peptide forming
6 helix bundle and resulting into fusion of the viral membrane to the host cell membrane [12].
This create the fusion pore.

Figure 4 : Formation of the fusion pore. Structural changes in the pre-fusion - post-fusion form
of the MeV F[13].
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1.8. Mechanism of action
H and F are responsible for attachment of the virus to the host cell and membrane
fusion. In order to fuse, F has to transform from a pre - fusion to a post-fusion form. This
transformation is triggered by H, which activates F refolding upon receptor binding. H and F
are known to form a complex within the infected cell [14-17]. They [13]travel to the plasma
membrane together and are incorporated into viral particles [14, 15, 18, 19]. H and F
interaction can be monitored through co-immunoprecipitation [20]. This assay utilizes the
chemical cross-linker DTSSP to covalently link the two proteins together. DTSSP will bind
with amino groups in lysine residues present on the surface of the H and F oligomers. The aim
of this study is to characterize the molecular interphase of the H and F hetero-oligomeric prefusion complex.
In order to achieve this goal, we identified lysine residues predicted to be located on the
surface of the pre-fusion F trimmer using the Pymol algorithm. Utilizing a homology model of
MeV F based on the crystal structure of PIV5 F protein, I highlighted the lysine residues that
were found on the outer surface of the protein structure; residues 111, 244, 248, 292, 364, 396,
410, 474, and 488. These lysine residues could have the potential to interact with DTSSP and
mediate covalent cross-links with H. To test the contribution of individual residues to crosslinking, we mutated the lysine residues to arginine. Arginine was chosen because of its
biophysical similarity to lysine. However, absence of a primary amino group in the side chain
prevents covalent amino-ester formation with DTSSP. I decided to mutate these lysines to
arginines stepwise, hypothesizing that arginine will not affect the biological activity of F or
protein folding, but prevent H-F crosslinking biochemically.
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Figure 5:: Structure of Fusion protein of MeV showing all the mutated lysine molecule sites. A
homology model of MeV F based on the crystal structure of PIV5 F protein. Model is build using
Pymol algorithm.
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2.
2.1

MATERIALS AND METHODS

Site directed mutagenesis
A site-directed mutagenesis technique was used to make specific and intentional

changes in the DNA sequence of a fusion protein of MeV. This is a linear amplification
technique, unlike standard PCR where we get exponential amplification of the product

Figure 6: General procedure for site directed mutagenesis [21].
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To change the lysines (K) in positions 111, 292, 244, 248, 364, 396, 410, 474, 488 to
arginine ( R ) primers were designed. Primer sequences for mutagenesis were:
•

F-K111R –F – GCTTCAAGTAGGAGACACAGGAGATTTGCGGGAGTAGTCC

•

F-K292R-F – GACGCTGTCCGAGATTAGGGGGGTGATTGTCCACCGGC

•

F-K396R –F – GTGCATCAATCCTTTGCAGGTGTTACACAACAGGAACG

•

F-K244-248R–FGGAGGAGACATCAATAGGGTGTTAGAAAGGCTCGGATACAGTGGAG

•

F-K364R-F – CTCCGGGGGTCCACTAGGTCCTGTGCTCGTACA

•

F-K410R-F

–

GATCATTAATCAAGACCCTGACAGGATCCTAACATACATTGCT
•

F-K474-F- GCTAAGTTGGAGGATGCCAGGGAATTGTTGGAGTC

•

F-K488R-F CAGATATTGAGGAGTATGAGAGGTTTATCGAGCAC

5 µl of the site-directed mutagenesis product was run on a 0.8% agarose gel to check
whether the bands are in the desired molecular weight range. We saw a band corresponding to
our product. To get rid of the parental DNA strand, we conducted DpnI digestion.
DpnI Digest: We added 1 µl of DpnI (20 U/µl, New England Biolabs) to the reaction
and incubated at 37◦C for overnight.

2.2.Transformation
To get higher quantities of the engineered plasmids, transformation was done.
Competent bacterial strain of E. coli was placed in a reaction tube. 2 µl of engineered plasmids
(site-directed mutagenesis product) were added to the bacterial culture and incubated on ice for
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30 min. Heat shock was given for 30 sec to the bacteria so that their cell membrane becomes
permeable to take up the plasmid. For recovery from heat shock, 200 µl of L.B. plain medium
was added in each tube and bacteria were incubated in 37°C incubator for 1 hr. and, bacteria
were inoculated on LB agar plates. 30 µl of 1000X Ampicillin/plate was used for positive
selection. The plates were incubated in 37°C incubator for overnight.
2.3. Mini prep
Colonies from each plate were selected and grown in 3 ml of LB Amp medium, for
overnight in 37°C shaker. To get high-purity plasmid DNA from the bacteria, the Qiagen mini
prep kit was used and protocol was followed.
To check whether our amplified plasmid was correct or not, DNA was digested with
suitable enzyme and incubated at 37°C overnight using Water + DNA 2 µl + Buffer 2 µl
+BSA + 0.5 µl of each enzyme (Total 20 µl). Digested according to the guidelines in the
enzyme / buffer book.
Agarose gel electrophoresis was carried out to make sure the DNA was the right size.
Concentration of DNA was determined using spectrophotometry. These DNAs were sent to
Genewiz Company for sequencing.
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Figure 7 General procedure for QIAgen mini-prep DNA purification [17]
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2.4.Midi Prep
Left over liquid bacterial culture from Mini prep was use to inoculate 200 ml LB Amp
medium. It was then incubated overnight in 37°C shaker. To generate more of the purified
DNA, Qiagen midi prep kit was used and the protocol was followed. The concentration of the
collected DNA was identified µg/µl with the spectrophotometer.
2.5.Cell lines used.
For these experiments we 150 W Vero cell line. These cells are isolated from African
Green Monkey’s epithelium cells of kidney [22]. These are immortalized cells used in tissue
culture. These cells stably expresses the plasmid encoding hSLAM= (human) signaling
lymphocytic activation molecule also called as CD150, which act as a receptor molecule for
measles H protein.[22-24] These cells are developed by Dr. Yusuke Yanagi, Kyushu University,
Kukuyoka, Japan [22, 24].
The virus do not infect these cells persistently makes these cells easy to maintain in the
laboratory conditions [22-24]. These cells need medium containing geneticin to stably express
SLAM. This makes these cells little expensive to maintain [22, 24].
2.6.Transfection
Using the concentration of DNA collected in Midi prep, the volume of DNA (H,F and
GFP) to be added in each well of plated cells were calculated. 50 µl/well of serum free DMEM
and µl/well of Gene juice was mixed well and incubated at RT for 5 min. Then 50 µl of this
mixture was added in each tube of DNA and incubated at RT for 10 min. then each tube was
added in respective wells drop-wise. Each well was labeled properly and plates were incubated
at 37°C for overnight. After 15-18 hr. the plates were observed under the microscope for fusion
activity.
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2.7.Quantitative cell-to-cell fusion assay
For quantitative cell-to-cell fusion assay Vero 150 W cells were transfected with 0.5 µg
of GFP, 0.5 µg of WT H, 0.5 µg of the F constructs. Fusion activity was detected after 12-15
hr. post transfection. The cells were photographed using 200X magnification fusion and by
comparing with WT F, cell-to-cell fusion, fusion activity was calculated for each mutant F.
2.8.Surface biotinylation assay
Vero cells 150W were transfected with 4 µg of F constructs and 0.5 µg of GFP. After
incubating transfected cells for 36 hr. at 37⁰C cell surface proteins were biotinylated with 0.5
mg/mL sulfosuccinimidyl-2-(biotinamido)ethyl-1,3-dithiopropionate (Thermo Scientific) for
20 min at 4 °C. 700µl of cleared supernatant were collected and allowed to bind with
Streptavidin beads in 4⁰C for 2 hr. Then samples were washed with Washing buffers I and II, 3
times each. Then the bound proteins were denatured with urea buffer buffer [200 mM Tris (pH
6.8), 8 M urea, 5% (wt/vol) SDS, 0.1 mM EDTA, 0.03% bromophenol blue, 1.5% (wt/vol)
DTT] for 30 min at 50 °C. The samples were run on 10% SDS/PAGE and blotted on PVD
membranes. The blots were blocked with 5% nonfat milk in 1xPBS, then treated with αHA
monoclonal primary antibodies for 2 hr. After thorough washing with 1xPBST 3times, 10 min
each, the membranes were treated with anti-mouse IgG light-chain conjugate- secondary
antibody for 1 hr. Then the membranes were treated with West-Dura buffers and imaged using
ChemiDoc XRS digital imaging system (Bio-Rad).[8]
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3. RESULTS
3.1. Single lysine to arginine mutations in F have mixed effects on fusion activity.
Fusion activity of the F mutants harboring single lysine to arginine substitutions protein
was assayed in Vero-SLAM cells. Upon co-expression of standard H and F in these cells,
extensive syncytia formation takes place. Control cells lacking F showed no fusion activity.
Taking these as reference, other cells expressing F mutants (F-K111R, F-K364R, F-K474R,
and F-K488R) showed strong fusion activity. However, F-K410R, F-K292R and F-K396R
returned reduced fusion activity.
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Figure 8 Fusion activity results. Each panel showing 150 W cells transfected with MeV H, GFP
and pCG EdmF-c3Xflag with MeV F having single mutation. When these cells express MeV’
functional H & F they tend to fuse together forming giant cell with multiple nuclei in it known as
syncytia.
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3.2. Double mutants F constructs
The single lysine to arginine mutations were then combined in different patterns and the
resulting F double mutants tested for fusion activity. Again, Vero-SLAM cells were transfected
with these DNA to check the fusion activity of the mutated F proteins. This experiment
revealed that F mutants F-K111-292R and F-K244-248R retained strong fusion activity.
However, fusion activity was reduced in cells expressing F-K111-364R and F-K292-396R
mutations.

Figure 9 Fusion activity results. Each panel showing 150 W cells transfected with MeV H, GFP
and pCG EdmF-c3Xflag with MeV F having double mutation
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3.3.Triple K to R mutants have better fusion activity than some of the double mutant
The F-K111-292R mutant displayed high fusion activity and these two residues are
naturally separated from the other mutation sites by single-cutting restriction enzyme site. This
enabled the convenient generation of triple mutation constructs through a straight-forward A-B
cloning technique. In this technique, we cut the specific piece of backbone harboring the
FK111-292R mutations with the SpeI and KpnI enzymes. In parallel, we also cut the plasmids
having the additional single mutations with the same enzymes, and then ligated the appropriate
DNA fragments after purification.

Figure 10 Schematic representation of A-B cloning technique.

Vero-SLAM cells were co-transfected with H-encoding plasmid DNA and the resulting
ligation products to determine the fusion activity of the mutated F constructs. The experiment
revealed that all the cells expressing F mutants with triple mutations formed extensive
syncytia, indicating high fusion activity of the F triple mutants.
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Figure 11: Fusion activity results. Each panel showing 150 W cells transfected with MeV H,
GFP and pCG EdmF-c3Xflag with MeV F having triple mutation
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3.4.Different constructs of MeV F with K-R mutations.
The constructs F-K111R, F-K292R, FK 364R, FK396R, FK410R, FK474R, FK488R
FK244-248R, FK111-291R, FK111-396R, and FK292-396R are made using site directed
mutagenesis technique. While the construct FK111-292-364R, FK111-292-396R, FK111-292410R, FK111-292-474R and FK111-292-488R are made using A-B cloning technique. To
amplify the DNA, the constructs were transformed in to the competent E. coli bacteria. Then
purified using QIAgen mini prep kit. The sequences were conformed from the Genewiz
sequencing company. After sequence conformation, to get more DNA, leftover bacterial
culture was grown in 200 ml of the LB medium in 37⁰C shaker overnight and then DNA was
purified using QIAgen midi-prep kit. The concentrations got in midi-prep purification are
shown in the Table 1. Then the fusion activity was checked by Fusion assay. Results for fusion
activity as compared to WT are shown in the table 1.
Table 1 Table showing different constructs of MeV F with K-R mutations in it

23

3.5.Grouping of certain mutations
After looking at the results from the previous fusion assays we observed that mutating
lysines to arginine affects the fusion activity of the F molecule. To get descent fusion activity
but still change the Fifure10.
244

244
248
111
292

111

111

292

292
396

410
Top

Top +410

Middle

111

111

292

292
396

396
410

364
Middle
+410

Mid Bottom

111
292
396
364

474
Stalk

Mid 488

Figure 12: Fusion protein of MeV showing Different groups of K-to-L mutations
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3.6. Fusion assay of different groups of MeV F constructs having K-to-R mutations and HA tag
To be able to coIP F with H with the help of DTSSP, we replaced c3XFlag tag in
EdmF with HA tag with A-B cloning method and also inserted K-R mutations so that we can
concentrate arginine instead of lysine at certain positions so that fusion activity is retained.
Figure 11 and 12 shows 3 field of views of each well of 12 well plate in which fusion assay for
different constructs of F in Vero 150W cells was carried out. From the fusion assay we
calculated bio activity of F compared with WT F (denoted in red types)

WT F (+4)

FK111-292-244248R-HA (Top, +2)

FK111-292-396RHA (Middle,+3)

F-K477-488R-HA
(Stalk,+4)
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WT F (+4)

FK111-292-364-396RHA (Mid – Bottom,+2)

FK364-410R-HA
(Bottom,+4)

Figure 13: Bio activity of H and F, each panel showing 150 W cells transfected with MeV
H, GFP and pCG EdmF-c2XHA. Three different views of one well of 12 well plate.

3.7.Different groups of constructs of MeV F with K-R mutations and HA tag in it.
The HA tag was inserted in place of the c-terminal 3x FLAG in the F construct using
A-B cloning technique. Different groups of F construct were created by adding mutations in
the f construct with site directed mutagenesis, they are as follows,
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Top

F-K111-292-244-248R-HA

Top+410

F-K111-292-244-248-410RHA

Middle

F-K111-292-396R-HA

Middle+410

F-K111-292-396-410R-HA

Mid-Bottom

F-K111-292-364-396R-HA

Bottom

F-K364-410R-HA

Stalk

F-K474-488R-HA

To amplify the DNA, the constructs were transformed in to the competent E. coli
bacteria. Then purified using QIAgen mini prep kit. The sequences were conformed from the
Genewiz sequencing company. After sequence conformation, to get more DNA, leftover
bacterial culture was grown in 200 ml of the LB medium in 37⁰C shaker overnight and then
DNA was purified using QIAgen midi-prep kit. The concentrations got in midi-prep
purification are shown in the Table 2. Then the fusion activity was checked by Fusion assay.
Results for fusion activity as compared to WT are shown in the table 2
Table 2: Table showing different constructs of MeV F with K-R mutations in it.
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3.8.Quantification of surface expression of F
To quantify surface expression of the different F on the cell surface we transfected
Vero cells 150 W with 4µg of different F constructs and 0.5µg of GFP and incubated in 37⁰C
incubator for 36 hr. Then surface biotinylation assay was performed as described in the
procedure. After the western blotting the blots were treated with West-Dura buffers and imaged
using ChemiDoc XRS digital imaging system (Bio-Rad). The intensity of the bands was
identified and compared with the WT F band. Then the percentage surface expression was
plotted against fusion activity. The graph is shown as bellow. Here we can see that In constructs
WT, A, C, D, E and G fusion activity is correlated with percent surface expression but in case of
B though percentage surface expression is very high, the fusion activity is significantly reduced.
Where as in case of construct F surface expression of the protein is very high.
Where
A- Top
B- Top + 410
C- Middle
D- Mid + Bottom
E- Middle + 410
F- Bottom
G- Stalk

Fₒ

F₁

Total Lysates

Figure 14: Surface biotinylation assay western blot showing Total lysates and
Surface biotinylated samples for different F constructs.
Stalk (F-K-474-488-R-HA)

Bottom (F-K-364-410-R-HA)

Mid-Bottom (F-K-111-292-364-396-R-HA)

Middle+410 (F-K-111-292-396-410-R-HA)

Middle (F-K-111-292-396-R-HA)

Top+410 (F-K-111-292-244-248-410-R-HA)

(-) ve control

Stalk (F-K-474-488-R-HA)

Bottom (F-K-364-410-R-HA)

Mid-Bottom (F-K-111-292-364-396-R-HA)

Middle+410 (F-K-111-292-396-410-R-HA)

Middle (F-K-111-292-396-R-HA)

Top+410 (F-K-111-292-244-248-410-R-HA)

Top (F-K-111-292-244-248-R-HA)

Fₒ

Top (F-K-111-292-244-248-R-HA)

F₁

(-) ve control

WT F

WT F
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Surface Biotinylated samples
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Figure 15 Graph plotted percent surface expression Vs Fusion activity of MeV F
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4. DISCUSSION
In this study we constructed various F construct s which have K-R mutations at certain
positions. These lysines were on the surface of the F molecule. Here we were hypothesizing
that when H and F interact, particular surface lysines in F and others in H would be 11-12 Å
from one another, enabling DTSSP to cross-link the two proteins. If we can identify pairs of
cross-linkable lysines between the two proteins, we can more precisely map the H-F interface.
In the first experiment we inserted single mutations at a time in pCG EdmF c3xflag
plasmid to get F-K111R, F-K292R, F-K364R, F-K396R, F-K410R, F-K474R and F-K488R
constructs. When we transfected 150W Vero cells with these constructs we observed fusion
activity by monitoring the size of the syncytia. The cells with the constructs F-K111R, FK364R, F-K474R and F-K488R showed large syncytia. But the cells with the constructs FK292R, F-K396R and F-K410R showed very small syncytia. Thus from these results we can
say that changing the lysine to arginine at certain positions changes the fusion activity of the F.
To check if we can regain the fusion activity by combining the two mutations (K-R) we added
second mutation in the construct which already has one mutation in it and created sets of F
constructs.
In the second experiment we created the sets of F constructs with two K-r mutations as
follows, F-K111-292R, FK111-396R, F-K292-396 and F-K244-248R. Here after infecting
150W Vero sells with these new constructs we observed that construct F-K111-292R and FK244-248R showed large syncytia which means after adding K111R mutation we regain the
fusion activity of K292R construct. But in case of the constructs FK111-396R and F-K292-396
the syncytia are very small.
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To get the constructs with maximum K-R mutations but at least 70% bioactive we
decided to add third mutation on the construct F-K111-292R. So we constructed F-K111-292364R, F-K111-292-244-248R, F-K111-292-396R, F-K111-292-410R, F-K111-292-474R and
F-K111-292-488R constructs. After infecting 150W Vero cells with these constructs we
observed that cells with constructs F-K111-292-364R, F-K111-292-474R and F-K111-292488R showed large syncytia but the construct F-K111-292-244-248R, F-K111-292-396R and
F-K111-292-410R showed small syncytia. By observing these results we cannot say that
combining the mutations which had shown good fusion activity on the construct with lower
fusion activity does not improves the fusion activity of the construct which had shown poor
fusion activity. Therefor for further experiments we decided to change lysine to arginine at
certain positions on the F protein.
In the fourth experiment we created groups of mutations which will change the surface
lysine to arginine at certain positions. Therefor we created constructs F-K111-244-248-292R
(Top), F-K111-44-248-292-410R (Top+410), F-K111-292-396R (Middle), F-K111-292-396410R (Middle+410), F-K111-292-364-396R (Mid-Bottom), F-K364-410R (Bottom) and FK474-488R (Stalk) (figure 10). In these constructs we also replaced flag tag with HA tag
because Haemaglutinin (H) also has flag tag and this is identified by the antibodies. If we have
flag tag in both the H and F then we will not be able to perform the coIP experiment. Here
when we infected 150W Vero cells with these constructs we observed large syncytia in FK111-292-396R (Middle), F-K364-410R (Bottom) and F-K474-488R (Stalk) but small
syncytia in F-K111-244-248-292R (Top), F-K111-44-248-292-410R (Top+410), F-K111-292396-410R (Middle+410) and F-K111-292-364-396R (Mid-Bottom). That means changing
lysines to arginine in the bottom and the stalk area of the F does not affect the fusion activity of
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the F but when we change the lysines from the top, middle portion of the head domain of the F
then the fusion activity is affected.
There are various reasons for the fusion activity of the F to go down. For instance, after
inserting mutation/s the protein may not fold properly, the F may not be cleaved properly into
F₁ and F₂ from F

in the late Golgi apparatus, due to the change/s the F may not make it up to

the cell surface, the F may not interact with H in the pre-fusion form, the H cannot make
conformational changes in the F after the receptor binding, the F is already in the post-fusion
form, etc. If F is not properly folded or not cut properly then there are high chances that it will
not be exposed out on the cell surface. So to check whether the mutated F construct can
produce the protein which is expressed on the cell surface or not, in the fifth experiment we
infected 150W Vero cells with these F constructs and quantify their surface expression with
surface biotinylation assay. In these assay we found out that in constructs F-K111-292-396R
(Middle), F-K111-292-396-410R (Middle+410), F-K111-292-364-396R (Mid-Bottom), FK364-410R (Bottom) and F-K474-488R (Stalk) sizes of the syncytia are comparable to the
surface expression of the protein. i.e. in the constructs F-K111-292-396R (Middle), F-K111292-396-410R (Middle+410), F-K364-410R (Bottom) and F-K474-488R (Stalk) when surface
expression goes up the size of the syncytia is large and when the surface expression goes down
the size of the syncytia decreases. But in case of the construct F-K111-44-248-292-410R
(Top+410) and F-K111-244-248-292R (Top) though they are expressed on the cell surface
very efficiently but the size of the syncytia are very small. There could be various reasons for
that, the protein is transported on just fine but either it is already in the post fusion form or it
cannot interact with H or H cannot induce conformational change in it after binding with the
receptor protein.
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5. CONCLUSION
From this study we found out that fusion activity of the F gets affected when lysine
residue from certain area are changed into arginine. In most of the cases when surface
expression of the F protein is higher the fusion activity is higher and when surface expression
of the protein is lower then the fusion activity is also lower. But in some constructs though
the surface expression of the protein is high but the fusion activity is still low, experiments to
find out the reason/s behind these have to be done.
Now we have different F constructs F-K111-244-248-292R (Top), F-K111-44-248292-410R (Top+410), F-K111-292-396R (Middle), F-K111-292-396-410R (Middle+410), FK111-292-364-396R (Mid-Bottom), F-K364-410R (Bottom) and F-K474-488R (Stalk) which
expresses on the cell surface and which have lysine to arginine mutations at certain positions
we can perform further experiment to map the H-F protein - protein interaction in MeV.
The findings of this study will be useful in further study of mapping of H and F interaction in
measles virus and eventually development of novel therapeutics against the disease.
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